52356

Cystourethroscopy, with resection or fulguration of ureteral or renal pelvic tumor

CPT code 52356 represents the endoscopic procedure of cystourethroscopy combined with resection or fulguration of a tumor located in the ureter or renal pelvis. This sophisticated procedure is performed by a urologist using a specialized instrument called a ureteroscope, which is a thin, flexible, or rigid lighted tube. The ureteroscope is advanced through the urethra, bladder (cystourethroscopy component), and then into the ureteral orifice, up the ureter, and into the renal pelvis. The primary objective is to visualize, identify, and treat abnormal growths or tumors within the upper urinary tract (ureter and renal pelvis). Upon locating the tumor, the physician uses specialized endoscopic instruments passed through the working channel of the ureteroscope to either resect (cut out) the tumor, typically using a laser fiber or an electrocautery loop, or to fulgurate (burn) the tumor tissue using an electrocautery or laser energy. The resected tissue is often retrieved for pathological examination to determine the tumor's nature (benign or malignant) and grade. This procedure is less invasive than open surgery and is often chosen for smaller, low-grade tumors, or as a diagnostic measure for suspicious lesions. It requires meticulous skill due to the delicate anatomy of the ureter and renal pelvis. Post-procedure, a ureteral stent may be placed to ensure proper drainage and prevent stricture formation, though its reporting depends on the specific circumstances.

Clinical Indications

  • Diagnosis and treatment of suspected or confirmed urothelial carcinoma of the ureter or renal pelvis.
  • Positive urine cytology suggestive of upper tract urothelial carcinoma without an identifiable bladder lesion on cystoscopy.
  • Unexplained hematuria with imaging (e.g., CT urogram) demonstrating a filling defect or mass in the ureter or renal pelvis.
  • Surveillance for patients with a history of upper tract urothelial carcinoma.
  • Evaluation and treatment of recurrent low-grade upper tract urothelial tumors.
  • Management of certain benign tumors or strictures that mimic tumors and require endoscopic removal or biopsy.

Procedure Steps

  1. Patient Preparation: Patient is placed in the dorsal lithotomy position under general or regional anesthesia.
  2. Cystourethroscopy: A cystoscope is inserted through the urethra into the bladder to inspect the bladder mucosa and identify the ureteral orifices.
  3. Ureteral Access: A guide wire is typically passed into the ureteral orifice and advanced up the ureter to the renal pelvis under fluoroscopic guidance.
  4. Ureteroscope Insertion: A ureteroscope (flexible or rigid) is advanced over the guide wire through the ureteral orifice, up the ureter, and into the renal pelvis.
  5. Tumor Identification: The ureter and renal pelvis are systematically inspected to identify the tumor or lesion.
  6. Resection/Fulguration: Specialized instruments (e.g., laser fiber, electrocautery probe, biopsy forceps, basket) are passed through the working channel of the ureteroscope to either resect (cut out) the tumor tissue or fulgurate (burn) it.
  7. Specimen Retrieval: If resection is performed, tissue fragments are retrieved using a basket or forceps for histopathological examination.
  8. Hemostasis: Any bleeding at the treatment site is controlled, typically with electrocautery or laser.
  9. Stent Placement (Optional but common): A ureteral stent may be placed at the end of the procedure to ensure urinary drainage and prevent ureteral stricture, especially after extensive manipulation or resection.
  10. Scope Removal: The ureteroscope and guide wire are carefully removed.

Coding Guidelines

  • Bundling: Code 52356 includes the cystourethroscopy, passage of a ureteral catheter (guide wire), and ureteroscopy necessary to reach the tumor site.
  • Unilateral Procedure: 52356 is inherently a unilateral procedure. If performed bilaterally, append Modifier -50 (Bilateral Procedure).
  • Stent Placement: If a ureteral stent (e.g., 52332) is placed solely for drainage after the procedure and is an integral part of the operative session, it is generally considered bundled. However, if the stent is placed for a separate and distinct reason (e.g., pre-operative placement for drainage due to obstruction or a prolonged, complicated procedure warranting a separate assessment for stent need) or if it's placed and later removed in a separate encounter, distinct billing might be considered with appropriate modifiers (e.g., -59 if placed for a separate, distinct reason on the same day). The CPT manual parenthetical note for 52356 states "For stent placement, see 52332." This suggests that 52332 can be separately reported if specific criteria for separate reporting are met, usually indicating it's not simply routine post-procedure drainage.
  • Biopsy Only: If a biopsy is taken but no resection or fulguration of a tumor is performed, other codes like 52354 (Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with biopsy and/or fulguration of lesion) might be more appropriate. 52356 specifically implies resection or fulguration of a tumor.
  • Imaging Guidance: Fluoroscopic guidance for advancement of the ureteroscope or placement of a stent (e.g., 74425) may be separately reportable if performed and documented by the operating physician, depending on specific payer policies and documentation of distinct professional work. In many facility settings, this guidance is often bundled into facility charges.

Associated ICD-10 Codes